Aspirin and immunotherapy: a Faustian bargain?
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
1
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Fibrinogen-like protein 1 (FGL1) has been associated with improved survival in hepatocellular carcinoma (HCC). However, recent evidence suggests that FGL1 may bind to surface receptors on lymphocytes and induce immune senescence. In this issue of the JCI, Lin and co-authors show that FGL1 may be acetylated by aspirin and targeted for degradation, which is associated with increased antitumor immunity and improved survival. Similar findings were obtained with inhibitors of sirtuin 2 (SIRT2), a histone deacetylase. These findings expand our current understanding of the role of FGL1 in cancer and provide an impetus for the evaluation of alternative immunotherapy combinations in HCC.
Identifiants
pubmed: 37115694
pii: 169598
doi: 10.1172/JCI169598
pmc: PMC10145917
doi:
pii:
Substances chimiques
Aspirin
R16CO5Y76E
Fibrinogen
9001-32-5
FGL1 protein, human
0
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentOn
Références
Biochem Biophys Res Commun. 2015 Sep 18;465(2):167-73
pubmed: 26225745
J Clin Oncol. 2017 Jun 1;35(16):1836-1844
pubmed: 28406723
J Int Med Res. 2022 Sep;50(9):3000605221126874
pubmed: 36173010
Front Oncol. 2020 Jan 14;9:1503
pubmed: 31993373
JAMA Oncol. 2018 Dec 1;4(12):1683-1690
pubmed: 30286235
PeerJ. 2020 Mar 13;8:e8654
pubmed: 32206449
Front Immunol. 2022 Jan 17;12:785091
pubmed: 35111155
Mol Biol Rep. 2022 Aug;49(8):7911-7919
pubmed: 35776395
Front Endocrinol (Lausanne). 2020 Jan 23;11:3
pubmed: 32038497
Cell. 2019 Jan 10;176(1-2):334-347.e12
pubmed: 30580966
Cancer Med. 2020 Oct;9(19):7125-7136
pubmed: 32810392
Nat Commun. 2023 Feb 10;14(1):735
pubmed: 36759517
Thromb Res. 2015 Jul;136(1):118-24
pubmed: 25496996
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Nat Commun. 2019 Jan 25;10(1):448
pubmed: 30683885
Med Oncol. 2014 Sep;31(9):181
pubmed: 25129313
Semin Cancer Biol. 2022 Oct;85:209-218
pubmed: 33705871
Onco Targets Ther. 2017 Sep 20;10:4645-4656
pubmed: 29033583
Oncologist. 2020 Mar;25(3):e602-e605
pubmed: 32162820
Front Oncol. 2022 Feb 22;12:810269
pubmed: 35273912
Hematol Oncol Clin North Am. 1992 Dec;6(6):1247-57
pubmed: 1333467
J Natl Cancer Inst. 2015 May 13;107(8):
pubmed: 25971300
J Oncol. 2022 Mar 29;2022:4664651
pubmed: 35392432
Biochim Biophys Acta. 2001 Jul 30;1520(1):45-53
pubmed: 11470158
J Clin Invest. 2023 May 1;133(9):
pubmed: 37115693
Int J Mol Sci. 2021 May 19;22(10):
pubmed: 34069373
Immunology. 2018 Jul;154(3):476-489
pubmed: 29341118
Cancer Manag Res. 2022 Jan 22;14:259-271
pubmed: 35115826
Int J Biol Sci. 2017 Jun 1;13(6):804-814
pubmed: 28656005